newsfilter
← Latest News
PR Newswire·

IDEAYA Biosciences to Announce Topline Results from Phase 2/3 OptimUM-02 Trial in Metastatic Uveal Melanoma on Monday, April 13, 2026

IDEAYA Biosciences, Inc. (NASDAQ: IDYA), a precision medicine oncology company, today announced plans to issue a joint IDEAYA and Servier pre-market...